Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-Based Differences in Long-Term Respiratory and Pulmonary Vascular Outcomes After Acute Pulmonary Embolism: A Propensity-Matched Analysis of 795,338 Patients.

Respiratory medicine·2026
Same author

Enhancing mentorship/sponsorship opportunities for pulmonary, critical care and sleep fellows through structured alumni engagement.

BMJ leader·2026
Same author

What ancient wisdom and science know about drivers to high performance in organisations.

BMJ leader·2026
Same author

Countermeasures for doctors' leadership handicaps.

BMJ leader·2026
Same author

Implementation and Assessment of a Novel Interprofessional Educational Initiative in the Medical Intensive Care Unit: A Mixed-Methods Evaluation.

ATS scholar·2026
Same author

Chronic Thromboembolic Pulmonary Disease Phenotypes Using Upright Invasive Cardiopulmonary Exercise Testing.

Pulmonary circulation·2026

Related Experiment Video

Updated: Jul 6, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Augmentation therapy in alpha-1 antitrypsin deficiency.

Gustavo A Heresi1, James K Stoller

  • 1Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.

Expert Opinion on Biological Therapy
|March 21, 2008
PubMed
Summary

Alpha-1 antitrypsin augmentation therapy can slow lung function decline in emphysema patients. This treatment is well-tolerated and may improve survival, though cost-effectiveness requires further study.

More Related Videos

Protein Transfection of Mouse Lung
04:21

Protein Transfection of Mouse Lung

Published on: May 15, 2013

Related Experiment Videos

Last Updated: Jul 6, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

Protein Transfection of Mouse Lung
04:21

Protein Transfection of Mouse Lung

Published on: May 15, 2013

Area of Science:

  • Pulmonology
  • Genetics
  • Pharmacology

Background:

  • Alpha-1 antitrypsin deficiency is a genetic disorder causing early-onset emphysema.
  • Exogenous enzyme supplementation is a recent therapeutic approach.

Purpose of the Study:

  • To review augmentation therapy using pooled human plasma alpha-1 antitrypsin for emphysema.
  • To assess its role as a specific treatment for alpha-1 antitrypsin deficiency-related emphysema.

Main Methods:

  • Medline search from 1966-2007 using keywords 'alpha-1 antitrypsin deficiency' and 'therapy'.
  • Focused on articles evaluating biochemical and clinical efficacy.

Main Results:

  • Augmentation therapy increases serum and epithelial lining fluid antiprotease levels above the protective threshold.
  • Evidence indicates a slowed decline in lung function.
  • Potential reductions in infection rates and enhanced survival were noted.

Conclusions:

  • Augmentation therapy is a well-tolerated treatment for emphysema in alpha-1 antitrypsin deficiency.
  • It demonstrates potential benefits in slowing disease progression and improving outcomes.
  • Cost-effectiveness remains an area for further investigation.